Ascletis Pharma Inc (2VJ) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.013x

Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has a cash flow conversion efficiency ratio of -0.013x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-33.98 Million ≈ $-39.73 Million USD) by net assets (€2.57 Billion ≈ $3.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ascletis Pharma Inc (2VJ) total market value for the company's overall valuation and market capitalisation.

Ascletis Pharma Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Ascletis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ascletis Pharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascletis Pharma Inc ranked by their cash flow conversion efficiency. See Ascletis Pharma Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Beijing Hotgen Biotech Co Ltd SHG:688068	0.001x
Apnimed, Inc. Common Stock NASDAQ:APMD	-0.077x
SJF Bank A/S CO:SJF	0.190x
Kailuan Energy Chemical Co Ltd SHG:600997	0.020x
Beijing Capital Development Co Ltd SHG:600376	-0.053x
Ladder Capital Corp Class A NYSE:LADR	0.028x
Paras Defence and Space Technologies Limited NSE:PARAS	-0.019x
FuelCell Energy Inc NASDAQ:FCEL	-0.037x

Annual Cash Flow Conversion Efficiency for Ascletis Pharma Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2025. View today's stock price for Ascletis Pharma Inc for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€1.93 Billion ≈ $2.26 Billion	€-416.78 Million ≈ $-487.25 Million	-0.215x	-24.03%
2024-12-31	€1.97 Billion ≈ $2.30 Billion	€-341.58 Million ≈ $-399.34 Million	-0.174x	-81.81%
2023-12-31	€2.34 Billion ≈ $2.74 Billion	€-223.79 Million ≈ $-261.64 Million	-0.096x	-70.37%
2022-12-31	€2.54 Billion ≈ $2.97 Billion	€-142.45 Million ≈ $-166.54 Million	-0.056x	-4.17%
2021-12-31	€2.73 Billion ≈ $3.19 Billion	€-146.93 Million ≈ $-171.78 Million	-0.054x	-89.06%
2020-12-31	€2.98 Billion ≈ $3.49 Billion	€-84.91 Million ≈ $-99.27 Million	-0.028x	-27.34%
2019-12-31	€3.32 Billion ≈ $3.89 Billion	€-74.34 Million ≈ $-86.91 Million	-0.022x	+20.65%
2018-12-31	€3.43 Billion ≈ $4.01 Billion	€-96.59 Million ≈ $-112.92 Million	-0.028x	+87.62%
2017-12-31	€869.83 Million ≈ $1.02 Billion	€-198.06 Million ≈ $-231.55 Million	-0.228x	-645.29%
2016-12-31	€409.08 Million ≈ $478.26 Million	€-12.50 Million ≈ $-14.61 Million	-0.031x	--

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$1.20 Billion

€1.02 Billion EUR

Market Cap Rank

#8195 Global

#1085 in Germany

Share Price

€0.97

Change (1 day)

+10.23%

52-Week Range

€0.88 - €1.99

All Time High

€1.99